Files
Download Full Text (507 KB)
Abstract
Chronic myelogenous leukemia (CML) is a cancer described by uncontrolled proliferation of bone marrow cells that develop into the cells of the blood (Chen, 2014). In this study, the synergy of two drugs, bosutinib and a PF were tested for their efficacy in chemotherapy. Bosutinib is a kinase inhibitor that blocks phosphorylation of key proteins in the cell cycle of CML cells that allow them to proliferate (Boschelli et al., 2010). PF is an inhibitor of the Chk-1 protein that regulates many of the cell cycle checkpoints (Zhang et al., 2009). Two cell lines from CML were used in this experiment, BAF3/T315I and Adult/T315I. Both of these cell lines had the T315I mutation that provides resistance to the common CML chemotherapy drug imatinib (Gleevec). The cultured cells were treated with both bosutinib at 0.3 – 0.4 μM and PF at 1 – 1.2 μM individually as well as simultaneously. Results showed that the combined treatment of bosutinib and PF caused a large increase in cell apoptosis. These results show the possibility of a novel and effective chemotherapy combination for CML.
Publication Date
2014
Subject Major(s)
Biomedical Engineering
Current Academic Year
Sophomore
Faculty Advisor/Mentor
Steven Grant
Sponsorship
Virginia Commonwealth University. Undergraduate Research Opportunities Program
Is Part Of
VCU Undergraduate Research Posters
Rights
© The Author(s)